Bausch Health Companies Inc.’s planned spin-out of Bausch + Lomb Inc. not only turns loose a portfolio of vision care products from surgical technologies to OTC drugs and dietary supplements, but also further opens a tap for paying down its debt.
Paying down Bausch Health’s debt, largely incurred during the previous management’s ill-advised expansion-by-acquisition strategy when the firm operated as Valeant...



